OM
CTMX icon

Opaleye Management’s CytomX Therapeutics CTMX Stock Holding History

Opaleye Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-450,000
Closed -$8.18M – 36
2017
Q3 		$8.18M Sell
450,000
-10,000
-2% -$156K 2.89% 11
2017
Q2 		$7.13M Buy
460,000
+120,000
+35% +$1.81M 2.98% 10
2017
Q1 		$5.87M Buy
340,000
+170,000
+100% +$2.24M 2.92% 11
2016
Q4 		$1.87M Buy
170,000
+10,000
+6% +$121K 1.1% 27
2016
Q3 		$2.51M Hold
160,000
– – 1.31% 28
2016
Q2 		$1.63M Buy
+160,000
New +$1.82M 1.09% 35

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Opaleye Management's CTMX Position: Q4 2017 in Review

Opaleye Management sold out of CytomX Therapeutics (CTMX) in Q4 2017, closing a stake of 450,000 shares — an estimated $8.18M sold.

Opaleye Management first reported a position in CTMX in Q2 2016 and held it in 6 quarters. The position peaked at $8.18M in Q3 2017. 119 funds tracked by Wall St. Rank hold CTMX as of Q4 2017.

  • Opaleye Management reported no remaining CytomX Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Opaleye Management sold 450,000 CytomX Therapeutics shares in Q4 2017, an estimated $8.18M.
  • Opaleye Management first reported a position in CytomX Therapeutics in Q2 2016 and held it in 6 quarters.
  • Opaleye Management's CytomX Therapeutics position peaked at $8.18M in Q3 2017.
  • 119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2017.

Based on Opaleye Management's 13F filing for Q4 2017, filed 9 Feb 2018.